Premium
Synthesis of 1‐[4‐(m‐tolyl)amino‐6‐quinazolinyl]‐3‐[ 14 C]‐methyl triazene: a radiolabeled probe for the combi‐targeting concept
Author(s) -
Matheson Stephanie L.,
Mzengeza Shadreck,
JeanClaude Bertrand J.
Publication year - 2003
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.713
Subject(s) - triazene , chemistry , alkylation , hydrolysis , liquid scintillation counting , quinazoline , stereochemistry , nuclear chemistry , radiochemistry , biochemistry , organic chemistry , catalysis
Abstract The synthesis of 1‐[4‐( m ‐tolyl)amino‐6‐quinazolinyl]‐3‐[ 14 C]‐methyl triazene (SMA41) is described. This triazene was designed to be hydrolyzed under physiological conditions to N 4 ‐ m ‐tolyl‐quinazoline‐4,6‐diamine (SMA52), a moderate inhibitor of the epidermal growth factor receptor (EGFR) and the DNA alkylating species [ 14 C]‐methyldiazonium. A radiolabeled probe was needed to test the hypothesis that in situ hydrolysis of SMA41 may induce alkylation of the ATP binding site of EGFR. 14 C‐SMA41 was obtained with a radiochemical yield of 21% and a specific activity of 54.6 mCi/mmol, as determined by HPLC quantitation and scintillation counting. Radio‐TLC analyses showed 98% radiochemical purity. Copyright © 2003 John Wiley & Sons, Ltd.